GSK's management of Flovent allowed it to 'game the system': Hassan
17th March 2026 Uncategorised 0More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, according to a report released by Sen. Maggie Hassan. The setup forced many users to pay higher prices and allowed the British drugmaker to avoid paying Medicaid rebates, the report says.
More: GSK's management of Flovent allowed it to 'game the system': Hassan
Source: fierce